Anti-NGF antibodies and methods using same

• US 7,449,616 B2
• Filed: 12/24/2003
• Issued: 11/11/2008
• Est. Priority Date: 12/24/2002
• Status: Active Grant

• Current Assignee: Rinat Neuroscience Corp. (Pfizer Inc.)
• Original Assignee: Pfizer Inc.
• Inventors: Rosenthal, Arnon, Pons, Jaume
• Primary Examiner(s): Blanchard; David J.
• Assistant Examiner(s): BRISTOL, LYNN ANNE
• Application Number:
  US10/745,775
• Publication Number:
  US 20040237124A1
• Time in Patent Office: 1,784 Days
• Field of Search: 424/133.1, 424/145.1, 530/388.24
• US Class Current: 800/6
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: A61P 19/02 for joint disorders, e.g. arthritis, arthrosis
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 25/02 for peripheral neuropathies
• CPC Class Codes: A61P 25/04 Centrally acting analgesics, e.g. opioids
• CPC Class Codes: A61P 25/28 for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 29/02 without antiinflammatory effect
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 7/00 Drugs for disorders of the blood or the extracellular fluid
• CPC Class Codes: A61P 9/06 Antiarrhythmics
• CPC Class Codes: C07K 16/22 against growth factors ; against growth regulators
• CPC Class Codes: C07K 2317/21 from primates, e.g. man
• CPC Class Codes: C07K 2317/24 containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
• CPC Class Codes: C07K 2317/55 Fab or Fab'
• CPC Class Codes: C07K 2317/56 variable (Fv) region, i.e. VH and/or VL
• CPC Class Codes: C07K 2317/565 Complementarity determining region [CDR]
• CPC Class Codes: C07K 2317/73 Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
• CPC Class Codes: C07K 2317/76 Antagonist effect on antigen, e.g. neutralization or inhibition of binding
• CPC Class Codes: C07K 2317/92 : Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

The invention concerns anti-NGF antibodies (such as anti-NGF antagonist antibodies), and polynucleotides encoding the same. The invention further concerns use of such antibodies and/or polynucleotides in the treatment and/or prevention of pain, including post-surgical pain, rheumatoid arthritis pain, and osteoarthritis pain.

Claims

1. An isolated antibody comprising:

1) a heavy chain variable region comprising;

(a) the CDR1 region shown in SEQ ID NO;

3,

(b) the CDR2 region shown in SEQ ID NO;

4, and

(c) the CDR3 region shown in SEQ ID NO;

5; and

2) a light chain variable region comprising;

(a) the CDR1 region shown in SEQ ID NO;

6;

(b) the CDR2 region shown in SEQ ID NO;

7, and

(c) the CDR3 region shown in SEQ ID NO;

8;

wherein the antibody binds NGF.

2. The antibody of claim 1, wherein the heavy chain variable region consists of the sequence shown in SEQ ID NO:

1.

3. The antibody of claim 1, wherein the light chain variable region consists of the sequence shown in SEQ ID NO:

2.

4. The antibody of claim 2, wherein the light chain variable region consists of the sequence shown in SEQ ID NO:

2.

5. The antibody of claim 1, wherein the heavy chain consists of the amino acid sequence shown in SEQ ID NO:

16.

6. The antibody of claim 1, wherein the light chain consists of the amino acid sequence shown in SEQ ID NO:

17.

7. The antibody of claim 5, wherein the light chain consists of the amino acid sequence shown in SEQ ID NO:

17.

8. The antibody of claim 1, wherein the antibody is humanized.

9. The antibody of claim 1, wherein the antibody is affinity matured.

10. The antibody of claim 1, wherein the antibody is a monoclonal antibody.

11. A pharmaceutical composition comprising (a) the antibody of claim 1, and (b) a pharmaceutically acceptable excipient.

12. A kit comprising the antibody of claim 1.